251 related articles for article (PubMed ID: 35154489)
1. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
3. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
Liu X; Ghosh D
Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
[TBL] [Abstract][Full Text] [Related]
4. KRAS
Hobbs GA; Der CJ
Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
[TBL] [Abstract][Full Text] [Related]
6. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
[TBL] [Abstract][Full Text] [Related]
7. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
8. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
Seguin L
Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
[TBL] [Abstract][Full Text] [Related]
9. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
10. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
[TBL] [Abstract][Full Text] [Related]
11. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.
Yuan F; Sun M; Liu Z; Liu H; Kong W; Wang R; Qian F
Theranostics; 2022; 12(3):1061-1073. PubMed ID: 35154474
[No Abstract] [Full Text] [Related]
12. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
13. The pervasiveness of macropinocytosis in oncological malignancies.
Commisso C
Philos Trans R Soc Lond B Biol Sci; 2019 Feb; 374(1765):20180153. PubMed ID: 30967003
[TBL] [Abstract][Full Text] [Related]
14. Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells.
Jeong S; Byun JK; Cho SJ; Chin J; Lee IK; Choi YK; Park KG
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400219
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M; Barbacid M
Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
[TBL] [Abstract][Full Text] [Related]
17. Targeting the undruggable oncogenic KRAS: the dawn of hope.
Asimgil H; Ertetik U; Çevik NC; Ekizce M; Doğruöz A; Gökalp M; Arık-Sever E; Istvanffy R; Friess H; Ceyhan GO; Demir IE
JCI Insight; 2022 Jan; 7(1):. PubMed ID: 35014625
[TBL] [Abstract][Full Text] [Related]
18. An exosome-mimicking membrane hybrid nanoplatform for targeted treatment toward Kras-mutant pancreatic carcinoma.
Deng L; Zhang H; Zhang Y; Luo S; Du Z; Lin Q; Zhang Z; Zhang L
Biomater Sci; 2021 Aug; 9(16):5599-5611. PubMed ID: 34250995
[TBL] [Abstract][Full Text] [Related]
19. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
20. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]